The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

8 OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic ...

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain, rash ...

Nivolumab plus ipilimumab showed a strong median overall survival (OS) advantage at 12 months and a trend toward overall ...

TUESDAY, April 15, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or ...

At 3 years, Opdivo plus Yervoy led to an overall survival rate of 38% in patients with unresectable or metastatic hepatocellular carcinoma, compared to 24% with lenvatinib or sorafenib monotherapy.